CRISPR Therapeutics AG CRSP
NASDAQ CRSP
$55.43 -0.01 (-0.02%)
At close: Oct 2, 2026 · 4:00 PM EDT

CRISPR Therapeutics AG (CRSP) Gains from Sales and Divestitures (2016)

Updated

CRISPR Therapeutics AG (CRSP) reported Gains from Sales and Divestitures of -$28,000 for Q1 2016.

Analysis

CRISPR Therapeutics AG (CRSP) Gains from Sales and Divestitures (2016) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 CRISPR Therapeutics AG 5.36 Bn 5.36 Bn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2016 -28,000.00
API Access

CRISPR Therapeutics AG Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=CRSP&period=max&api_key=YOUR_API_KEY